Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 itepekimab versus placebo in moderate-to-severe COPD
NL-OMON54121Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) comparing Itepekimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe acute exacerbation of COPD in former smokers. Started Sep 2021; status: recruiting.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NL-OMON54121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54121.